Just thought you would like to know what your donation is doing - THANK YOU all so much for your support and hope to see you on the 20th!
|
| 
Dear Friend of LLS: I am pleased to share exciting news about Larry Kwak, M.D., Ph.D., a researcher funded by The Leukemia & Lymphoma Society. Dr. Kwak was recently named one of TIME Magazine's "100 Most Influential People," for his role in advancing custom-made vaccines for patients with lymphoma.
Dr. Kwak, professor and chair of the Department of Lymphoma and Myeloma at The University of Texas M.D. Anderson Cancer Center in Houston, has focused his work on harnessing the power of the immune system of patients with follicular non-Hodgkin's lymphoma to fight their cancer. The vaccines are developed by taking proteins from the patient's own tumor, training them to find and kill lymphoma cells and then injecting them back into the patient. Currently in late stage clinical trials, the vaccines have been shown to extend disease-free survival for more than a year.
In 2007, LLS awarded Dr. Kwak a five-year, $6.25 million Specialized Center of Research grant, our most prestigious research award. These grants are distinctive in that they encourage at least three laboratories at the same or different institutions to work together. In addition to continuing his work on the personalized lymphoma vaccines, this grant is enabling Dr. Kwak to expand his research to develop immunotherapies for patients with leukemia and myeloma as well.
Throughout his distinguished career, Dr. Kwak has been on the cutting edge of researching and developing novel immunotherapies that are already showing a clear benefit for patients with cancer. We are proud of Dr. Kwak's well-deserved recognition and are honored to have played a role in helping to advance this life-saving work.
To read more about Dr. Kwak's inclusion in the "2010 Time 100" please visit Time Magazine's website, and to learn more about our Research programs visit www.LLS.org. Please join us in taking pride in Dr. Kwak's achievements. Sincerely,
John E. Walter
President & CEO
|
0 comments:
Post a Comment